{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:57:36Z","timestamp":1791352656751,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T00:00:00Z","timestamp":1324252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T00:00:00Z","timestamp":1324252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2012,8,9]]},"DOI":"10.1038\/onc.2011.542","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T11:57:32Z","timestamp":1324295852000},"page":"3733-3740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["NPM-ALK signals through glycogen synthase kinase 3\u03b2 to promote oncogenesis"],"prefix":"10.1038","volume":"31","author":[{"given":"S R P","family":"McDonnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Basrur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K P","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Fermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Wey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Murga-Zamalloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K S J","family":"Elenitoba-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,19]]},"reference":[{"key":"BFonc2011542_CR1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1182\/blood-2007-04-060715","volume":"110","author":"HM Amin","year":"2007","unstructured":"Amin HM, Lai R . (2007). Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110: 2259\u20132267.","journal-title":"Blood"},{"key":"BFonc2011542_CR2","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1128\/MCB.18.12.6951","volume":"18","author":"RY Bai","year":"1998","unstructured":"Bai RY, Dieter P, Peschel C, Morris SW, Duyster J . (1998). Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 6951\u20136961.","journal-title":"Mol Cell Biol"},{"key":"BFonc2011542_CR3","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","volume":"17","author":"D Bischof","year":"1997","unstructured":"Bischof D, Pulford K, Mason DY, Morris SW . (1997). Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312\u20132325.","journal-title":"Mol Cell Biol"},{"key":"BFonc2011542_CR4","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2008-06-161018","volume":"113","author":"FE Boccalatte","year":"2009","unstructured":"Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L et al. (2009). The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase\/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113: 2776\u20132790.","journal-title":"Blood"},{"key":"BFonc2011542_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0014-4827(71)90599-4","volume":"68","author":"CJ Bostock","year":"1971","unstructured":"Bostock CJ, Prescott DM, Kirkpatrick JB . (1971). An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. Exp Cell Res 68: 163\u2013168.","journal-title":"Exp Cell Res"},{"key":"BFonc2011542_CR6","doi-asserted-by":"publisher","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","volume":"274","author":"AH Boulares","year":"1999","unstructured":"Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S et al. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932\u201322940.","journal-title":"J Biol Chem"},{"key":"BFonc2011542_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/35096075","volume":"2","author":"P Cohen","year":"2001","unstructured":"Cohen P, Frame S . (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769\u2013776.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc2011542_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785\u2013789.","journal-title":"Nature"},{"key":"BFonc2011542_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1101\/gad.11.8.957","volume":"11","author":"JA Diehl","year":"1997","unstructured":"Diehl JA, Zindy F, Sherr CJ . (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957\u2013972.","journal-title":"Genes Dev"},{"key":"BFonc2011542_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.4161\/cc.8.9.8302","volume":"8","author":"A Fernandez-Vidal","year":"2009","unstructured":"Fernandez-Vidal A, Mazars A, Gautier EF, Prevost G, Payrastre B, Manenti S . (2009). Upregulation of the CDC25A phosphatase down-stream of the NPM\/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle 8: 1373\u20131379.","journal-title":"Cell Cycle"},{"key":"BFonc2011542_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"S Frame","year":"2001","unstructured":"Frame S, Cohen P, Biondi RM . (2001). A common phosphate-binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321\u20131327.","journal-title":"Mol Cell"},{"key":"BFonc2011542_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. (2010). Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116: 2078\u20132088.","journal-title":"Blood"},{"key":"BFonc2011542_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/cgt.2010.20","volume":"17","author":"M Ito","year":"2010","unstructured":"Ito M, Zhao N, Zeng Z, Chang CC, Zu Y . (2010). Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Cancer Gene Ther 17: 633\u2013644.","journal-title":"Cancer Gene Ther"},{"key":"BFonc2011542_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.onc.1200849","volume":"14","author":"T Iwahara","year":"1997","unstructured":"Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439\u2013449.","journal-title":"Oncogene"},{"key":"BFonc2011542_CR15","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/j.1460-2075.1994.tb06417.x","volume":"13","author":"S Jinno","year":"1994","unstructured":"Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H et al. (1994). Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13: 1549\u20131556.","journal-title":"EMBO J"},{"key":"BFonc2011542_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","volume":"29","author":"RS Jope","year":"2004","unstructured":"Jope RS, Johnson GV . (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95\u2013102.","journal-title":"Trends Biochem Sci"},{"key":"BFonc2011542_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2007.12.002","volume":"13","author":"T Kang","year":"2008","unstructured":"Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC et al. (2008). GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13: 36\u201347.","journal-title":"Cancer Cell"},{"key":"BFonc2011542_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591\u2013594.","journal-title":"Blood"},{"key":"BFonc2011542_CR19","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood-2009-02-204735","volume":"114","author":"MS Lim","year":"2009","unstructured":"Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF et al. (2009). The proteomic signature of NPM\/ALK reveals deregulation of multiple cellular pathways. Blood 114: 1585\u20131595.","journal-title":"Blood"},{"key":"BFonc2011542_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.onc.1209843","volume":"26","author":"M Marzec","year":"2006","unstructured":"Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA . (2006). Oncogenic tyrosine kinase NPM\/ALK induces activation of the MEK\/ERK signaling pathway independently of c-Raf. Oncogene 26: 813\u2013821.","journal-title":"Oncogene"},{"key":"BFonc2011542_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","volume":"21","author":"U Maurer","year":"2006","unstructured":"Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR . (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749\u2013760.","journal-title":"Mol Cell"},{"key":"BFonc2011542_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.chembiol.2003.11.010","volume":"10","author":"L Meijer","year":"2003","unstructured":"Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M et al. (2003). GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1255\u20131266.","journal-title":"Chem Biol"},{"key":"BFonc2011542_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281\u20131284.","journal-title":"Science"},{"key":"BFonc2011542_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1021\/ml100158s","volume":"1","author":"GR Ott","year":"2010","unstructured":"Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV . (2010). Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett 1: 493\u2013498.","journal-title":"ACS Med Chem Lett"},{"key":"BFonc2011542_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20090387","volume":"420","author":"RH Palmer","year":"2009","unstructured":"Palmer RH, Vernersson E, Grabbe C, Hallberg B . (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345\u2013361.","journal-title":"Biochem J"},{"key":"BFonc2011542_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0301-472X(03)00007-9","volume":"31","author":"H Ruchatz","year":"2003","unstructured":"Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C . (2003). Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM\/ALK-transformed cells. Exp Hematol 31: 309\u2013315.","journal-title":"Exp Hematol"},{"key":"BFonc2011542_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nbt1046","volume":"23","author":"J Rush","year":"2005","unstructured":"Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ et al. (2005). Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94\u2013101.","journal-title":"Nat Biotechnol"},{"key":"BFonc2011542_CR28","first-page":"2194","volume":"61","author":"A Slupianek","year":"2001","unstructured":"Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L et al. (2001). Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61: 2194\u20132199.","journal-title":"Cancer Res"},{"key":"BFonc2011542_CR29","doi-asserted-by":"publisher","first-page":"17901","DOI":"10.1074\/jbc.M111635200","volume":"277","author":"M van Noort","year":"2002","unstructured":"van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H . (2002). Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 17901\u201317905.","journal-title":"J Biol Chem"},{"key":"BFonc2011542_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C . (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39\u201351.","journal-title":"J Immunol Methods"},{"key":"BFonc2011542_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","volume":"21","author":"A Zamo","year":"2002","unstructured":"Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. (2002). Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21: 1038\u20131047.","journal-title":"Oncogene"},{"key":"BFonc2011542_CR32","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1128\/MCB.00153-07","volume":"27","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL et al. (2007). Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 27: 4328\u20134339.","journal-title":"Mol Cell Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2011542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011542","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:05:03Z","timestamp":1647885903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2011542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,19]]},"references-count":32,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2012,8,9]]}},"alternative-id":["BFonc2011542"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.542","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,19]]},"assertion":[{"value":"14 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}